NO20084830L - C-fenylglycitolforbindelse for behandling av diabetes - Google Patents
C-fenylglycitolforbindelse for behandling av diabetesInfo
- Publication number
- NO20084830L NO20084830L NO20084830A NO20084830A NO20084830L NO 20084830 L NO20084830 L NO 20084830L NO 20084830 A NO20084830 A NO 20084830A NO 20084830 A NO20084830 A NO 20084830A NO 20084830 L NO20084830 L NO 20084830L
- Authority
- NO
- Norway
- Prior art keywords
- group
- phenylglycitol
- formula
- compound
- diabetes
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 2
- 230000000694 effects Effects 0.000 abstract 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 2
- 239000008103 glucose Substances 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 abstract 1
- 125000006590 (C2-C6) alkenylene group Chemical group 0.000 abstract 1
- 108091006277 SLC5A1 Proteins 0.000 abstract 1
- 108091006269 SLC5A2 Proteins 0.000 abstract 1
- 102000058090 Sodium-Glucose Transporter 1 Human genes 0.000 abstract 1
- 102000058081 Sodium-Glucose Transporter 2 Human genes 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000029142 excretion Effects 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 210000002700 urine Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
- C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrane Compounds (AREA)
Abstract
Det er tilveiebrakt en ny C-fenylglycitolforbindelse som kan tjene som et profylaktisk eller terapeutisk middel for diabetes ved å inhibere både SGLTl aktivitet og SGLT2 aktivitet og derved utvise en glukoseabsorpsjonsundertrykkende virkning og en virkning på uringlukoseutskillelse. En C-fenylglycitolforbindelse representert ved formel (I) nedenfor eller et farmasøytisk aksepterbart salt derav eller et hydrat derav hvori R1 og R2 er like eller forskjellige og representerer et hydrogenatom, en hydroksylgruppe, en C1-6-alkylgruppe, en C1-6-alkoksygruppe eller et halogenatom, R3 er et hydrogenatom, en C1-6-alkylgruppe, en C1-6-alkoksy-gruppe eller et halogenatom, Y er en C1-6-alkylengruppe, -0-(CH2)n- (n er et helt tall fra 1 til 4) eller en C2-6-alkenylengruppe, med den betingelse at når Z er -NHC (=NH) NH2 eller -NHCON (RB) Rc, da er ikke n lik 1, Z is -CONHRA, -NHC (=NH) NH2 eller -NHCON (RB) Rc, formel (A) eller formel (B).S
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006139891 | 2006-05-19 | ||
JP2006200033 | 2006-07-21 | ||
PCT/JP2007/060653 WO2007136116A2 (en) | 2006-05-19 | 2007-05-18 | C-phenyl glycitol compound for the treatment of diabetes |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20084830L true NO20084830L (no) | 2009-02-19 |
Family
ID=38617514
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20084830A NO20084830L (no) | 2006-05-19 | 2008-11-17 | C-fenylglycitolforbindelse for behandling av diabetes |
Country Status (15)
Country | Link |
---|---|
US (1) | US7973012B2 (no) |
EP (1) | EP2076503B1 (no) |
JP (1) | JP5067644B2 (no) |
KR (1) | KR20090016456A (no) |
CN (1) | CN101490028B (no) |
AR (1) | AR061026A1 (no) |
AU (1) | AU2007252432B2 (no) |
BR (1) | BRPI0711949A2 (no) |
CA (1) | CA2652707A1 (no) |
MX (1) | MX2008014512A (no) |
NO (1) | NO20084830L (no) |
NZ (1) | NZ573687A (no) |
RU (1) | RU2437876C2 (no) |
TW (1) | TW200812995A (no) |
WO (1) | WO2007136116A2 (no) |
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8198464B2 (en) | 2006-12-21 | 2012-06-12 | Astellas Pharma Inc. | Method for producing C-glycoside derivative and intermediate for synthesis thereof |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
KR101107425B1 (ko) | 2007-08-23 | 2012-01-19 | 테라코스, 인코포레이티드 | 벤질벤젠 유도체 및 사용 방법 |
CN102026970B (zh) | 2007-11-21 | 2013-07-31 | 解码遗传Ehf公司 | 用于治疗肺部和心血管病症的联芳基pde4抑制剂 |
UA101004C2 (en) | 2007-12-13 | 2013-02-25 | Теракос, Инк. | Derivatives of benzylphenylcyclohexane and use thereof |
KR101516677B1 (ko) * | 2008-01-31 | 2015-05-04 | 고토부키 세이야쿠 가부시키가이샤 | 지방성 간 질환의 치료용 의약 조성물 |
EP2668953A1 (en) * | 2008-05-22 | 2013-12-04 | Bristol-Myers Squibb Company | Pharmaceutical compositions comprising an SGLT2 inhibitor with a supply of carbohydrate and/or an inhibitor of uric acid synthesis |
US9061060B2 (en) | 2008-07-15 | 2015-06-23 | Theracos Inc. | Deuterated benzylbenzene derivatives and methods of use |
WO2010022313A2 (en) | 2008-08-22 | 2010-02-25 | Theracos, Inc. | Processes for the preparation of sglt2 inhibitors |
SG173587A1 (en) * | 2009-02-13 | 2011-09-29 | Boehringer Ingelheim Int | Sglt-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance or hyperglycemia |
JP5505741B2 (ja) | 2009-02-23 | 2014-05-28 | 大正製薬株式会社 | Sglt1阻害剤としての4−イソプロピルフェニルグルシトール化合物 |
US10610489B2 (en) | 2009-10-02 | 2020-04-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof |
PT2496583E (pt) | 2009-11-02 | 2015-01-14 | Pfizer | Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol |
AR079438A1 (es) | 2009-12-09 | 2012-01-25 | Panacea Biotec Ltd | Derivados de azucar, composiciones farmaceuticas y sus usos |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
US8575114B2 (en) | 2010-03-23 | 2013-11-05 | Albany Molecular Research, Inc. | SGLT-2 inhibitors, methods of making them, and uses thereof |
WO2011153712A1 (en) | 2010-06-12 | 2011-12-15 | Theracos, Inc. | Crystalline form of benzylbenzene sglt2 inhibitor |
WO2011157827A1 (de) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
JP2013224263A (ja) * | 2010-08-19 | 2013-10-31 | Taisho Pharmaceutical Co Ltd | 4−イソプロピルフェニルグルシトール化合物 |
JP5817317B2 (ja) * | 2010-08-20 | 2015-11-18 | 大正製薬株式会社 | 4−イソプロピルフェニルグルシトール化合物を有効成分として含有することを特徴とする糖尿病の予防又は治療剤 |
TW201219414A (en) | 2010-08-20 | 2012-05-16 | Taisho Pharmaceutical Co Ltd | Crystal form of 4-isopropylphenyl glucitol compound and process for production thereof |
WO2012023600A1 (ja) | 2010-08-20 | 2012-02-23 | 大正製薬株式会社 | 4-イソプロピル-6-メトキシフェニル グルシトール化合物 |
CN102453026A (zh) * | 2010-10-27 | 2012-05-16 | 上海艾力斯医药科技有限公司 | C-芳基葡糖苷衍生物、制备方法及其应用 |
EP2683705B1 (de) | 2011-03-08 | 2015-04-22 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US8710050B2 (en) | 2011-03-08 | 2014-04-29 | Sanofi | Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
JP6117186B2 (ja) * | 2011-05-20 | 2017-04-19 | ヤンセン ファーマシューティカ エヌ.ベー. | Sglt−2の阻害物質として有用な化合物の製造方法 |
KR101719758B1 (ko) | 2011-06-25 | 2017-03-24 | 수안주 파마 코포레이션 리미티드 | 씨 글루코사이드 유도체 |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP2755722B1 (en) | 2011-09-13 | 2017-05-24 | Panacea Biotec Ltd. | Novel sglt inhibitors |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
US9193751B2 (en) | 2012-04-10 | 2015-11-24 | Theracos, Inc. | Process for the preparation of benzylbenzene SGLT2 inhibitors |
UA113086C2 (xx) | 2012-05-10 | 2016-12-12 | Піразольні сполуки як інгібітори sglt1 | |
TW201425326A (zh) | 2012-10-05 | 2014-07-01 | Lilly Co Eli | 新穎脲化合物 |
FR2998202B1 (fr) * | 2012-11-19 | 2015-04-17 | Centre Nat Rech Scient | Soudage heterogene aluminium/cuivre |
DK3489226T3 (da) | 2012-11-20 | 2021-04-26 | Lexicon Pharmaceuticals Inc | Hæmmere for natriumglucose-cotransporter 1 |
AU2014213251B2 (en) | 2013-02-04 | 2017-07-20 | Taisho Pharmaceutical Co., Ltd. | Prophylactic or therapeutic drug for constipation |
US20140303097A1 (en) | 2013-04-05 | 2014-10-09 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US11813275B2 (en) | 2013-04-05 | 2023-11-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
PT2981271T (pt) | 2013-04-05 | 2019-02-19 | Boehringer Ingelheim Int | Utilizações terapêuticas de empagliflozina |
CN105377266A (zh) | 2013-04-18 | 2016-03-02 | 勃林格殷格翰国际有限公司 | 药物组合物、治疗方法及其用途 |
CN105611920B (zh) | 2013-10-12 | 2021-07-16 | 泰拉科斯萨普有限责任公司 | 羟基-二苯甲烷衍生物的制备 |
AR098670A1 (es) * | 2013-11-08 | 2016-06-08 | Lilly Co Eli | Inhibidor de sglt1 |
US9315438B2 (en) | 2014-01-03 | 2016-04-19 | Xuanzhu Pharma Co., Ltd | Optically pure benzyl-4-chlorophenyl-C-glucoside derivative |
WO2017141202A1 (en) | 2016-02-17 | 2017-08-24 | Lupin Limited | Complex of sglt2 inhibitor and process for preparation thereof |
CN107540706A (zh) * | 2016-06-28 | 2018-01-05 | 山东诚创医药技术开发有限公司 | 伊格列净中间体的制备方法 |
CN106632223B (zh) * | 2016-08-24 | 2019-04-23 | 浙江美诺华药物化学有限公司 | 2-(3-溴-4-(3-氟苄氧基)苯基)-1,3-二氧戊环及其制备方法 |
CN108033876A (zh) * | 2017-12-20 | 2018-05-15 | 江汉大学 | 一种5-溴-2-氯苯甲醛的制备方法 |
CN110066302B (zh) | 2018-01-23 | 2022-12-27 | 广东东阳光药业有限公司 | 吡喃葡萄糖基衍生物及其用途 |
US11186602B2 (en) | 2018-01-31 | 2021-11-30 | Sunshine Lake Pharma Co., Ltd. | Glucopyranosyl derivative and use thereof |
CN108610385A (zh) * | 2018-04-23 | 2018-10-02 | 中国科学院成都生物研究所 | 一种钠-葡萄糖协同转运蛋白1抑制剂的药物用途 |
US20230086354A1 (en) * | 2019-07-10 | 2023-03-23 | Sunshine Lake Pharma Co., Ltd. | Glucopyranosyl derivatives and their uses |
JP2023526699A (ja) * | 2020-05-15 | 2023-06-22 | 上▲海▼▲哲▼▲イェ▼生物科技有限公司 | アリールグルコシド誘導体及び薬物におけるその使用 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE216704T1 (de) | 1996-12-26 | 2002-05-15 | Tanabe Seiyaku Co | Propiophenonderivate und verfahren zu ihrer herstellung |
AU6024998A (en) | 1997-01-15 | 1998-08-07 | Glycomed Incorporated | Aryl c-glycoside compounds and sulfated esters thereof |
PH12000002657B1 (en) * | 1999-10-12 | 2006-02-21 | Bristol Myers Squibb Co | C-aryl glucoside SGLT2 inhibitors |
TR200202200T2 (tr) | 2000-03-17 | 2002-12-23 | Kissei Pharmaceutical Co., Ltd. | Glükopiranosiloksibenzilbenzen türevleri, bu türevleri ihtiva eden tıbbi bileşimler ve türevlerin hazırlanması için ara-maddeler. |
US6683056B2 (en) * | 2000-03-30 | 2004-01-27 | Bristol-Myers Squibb Company | O-aryl glucoside SGLT2 inhibitors and method |
JP4399251B2 (ja) * | 2001-05-30 | 2010-01-13 | キッセイ薬品工業株式会社 | グルコピラノシルオキシピラゾール誘導体、それを含有する医薬組成物、その医薬用途およびその製造中間体 |
ATE469161T1 (de) | 2002-08-08 | 2010-06-15 | Kissei Pharmaceutical | Pyrazolderivat, dieses enthaltende medizinische zusammensetzung, medizinische verwendung davon, und zwischenprodukt für dessen herstellung |
JP2004137245A (ja) | 2002-08-23 | 2004-05-13 | Kissei Pharmaceut Co Ltd | ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体 |
JP4606876B2 (ja) | 2002-08-27 | 2011-01-05 | キッセイ薬品工業株式会社 | ピラゾール誘導体、それを含有する医薬組成物及びその医薬用途 |
AU2003289156A1 (en) | 2002-12-04 | 2004-06-23 | Kissei Pharmaceutical Co., Ltd. | Preventive or remedy for diseases caused by hyperglycemia |
SI1730131T1 (sl) * | 2004-03-16 | 2012-08-31 | Boehringer Ingelheim Int | Glukopiranozil-substituirani benzenski derivati, zdravila, ki vsebujejo te spojine, njihova uporaba in postopek za njihovo pripravo |
DE102004028241B4 (de) | 2004-06-11 | 2007-09-13 | Sanofi-Aventis Deutschland Gmbh | Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel |
TW200637839A (en) * | 2005-01-07 | 2006-11-01 | Taisho Pharmaceutical Co Ltd | 1-thio-d-glucitol derivatives |
-
2007
- 2007-05-18 KR KR1020087028695A patent/KR20090016456A/ko not_active Application Discontinuation
- 2007-05-18 TW TW096118086A patent/TW200812995A/zh unknown
- 2007-05-18 EP EP07744087.3A patent/EP2076503B1/en active Active
- 2007-05-18 CN CN2007800271552A patent/CN101490028B/zh not_active Expired - Fee Related
- 2007-05-18 WO PCT/JP2007/060653 patent/WO2007136116A2/en active Application Filing
- 2007-05-18 BR BRPI0711949-6A patent/BRPI0711949A2/pt not_active IP Right Cessation
- 2007-05-18 AR ARP070102161A patent/AR061026A1/es not_active Application Discontinuation
- 2007-05-18 US US12/301,463 patent/US7973012B2/en not_active Expired - Fee Related
- 2007-05-18 RU RU2008150383/04A patent/RU2437876C2/ru not_active IP Right Cessation
- 2007-05-18 JP JP2009510714A patent/JP5067644B2/ja not_active Expired - Fee Related
- 2007-05-18 CA CA002652707A patent/CA2652707A1/en not_active Abandoned
- 2007-05-18 AU AU2007252432A patent/AU2007252432B2/en not_active Ceased
- 2007-05-18 NZ NZ573687A patent/NZ573687A/en not_active IP Right Cessation
- 2007-05-18 MX MX2008014512A patent/MX2008014512A/es active IP Right Grant
-
2008
- 2008-11-17 NO NO20084830A patent/NO20084830L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
NZ573687A (en) | 2010-10-29 |
BRPI0711949A2 (pt) | 2012-01-17 |
AU2007252432A1 (en) | 2007-11-29 |
AR061026A1 (es) | 2008-07-30 |
JP2009537509A (ja) | 2009-10-29 |
EP2076503A2 (en) | 2009-07-08 |
TW200812995A (en) | 2008-03-16 |
CN101490028A (zh) | 2009-07-22 |
CA2652707A1 (en) | 2007-11-29 |
MX2008014512A (es) | 2008-11-27 |
RU2437876C2 (ru) | 2011-12-27 |
EP2076503B1 (en) | 2013-07-17 |
AU2007252432B2 (en) | 2011-11-17 |
WO2007136116A3 (en) | 2008-03-13 |
WO2007136116A2 (en) | 2007-11-29 |
CN101490028B (zh) | 2013-02-06 |
RU2008150383A (ru) | 2010-06-27 |
JP5067644B2 (ja) | 2012-11-07 |
US20100022460A1 (en) | 2010-01-28 |
US7973012B2 (en) | 2011-07-05 |
KR20090016456A (ko) | 2009-02-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20084830L (no) | C-fenylglycitolforbindelse for behandling av diabetes | |
NO20085240L (no) | C-fenyl-1-tioglucitolforbindelse | |
NO20084127L (no) | Benzylfenylglukopyranosidderivat | |
NO20062583L (no) | Difenylazetidinonderivater med kolesterolabsorpsjonsinhiberende aktivitet | |
NO20084968L (no) | Dihydropyrazolpyrimidinonderivater | |
NO20081315L (no) | Benzokinazolinderivater og deres anvendelse ved behandling av benlidelser | |
NO20092286L (no) | Nitrogenhaldige heterosykliske forbindelser og anvendelse derav | |
MY129023A (en) | Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containing the same | |
NO20060823L (no) | Benzimidazol, benztiazol og benzoksazol derivater og deres anvendelse som LTA4H modulatorer | |
NO20083207L (no) | Inhibitorer av IAP | |
EA200800172A1 (ru) | 2,4-диаминопиримидины как ингибиторы aurora | |
NO20080675L (no) | P38-Map kinaseinhibitorer og metoder for deres anvendelse | |
NO20082090L (no) | Pyridopyrimidinoninhibitorer av P13K alfa | |
NO20085176L (no) | Fenyl substituerte heteroaryl-derivater og andvendelse som anti-tumor agenter | |
NO20084845L (no) | 2-pyrazinonderivater for behandling av sykdom eller tilstander der inhibiering av neutrofil elastaseaktivitetet er gunstig | |
NO20070323L (no) | Organiske forbindelser | |
NO20056192L (no) | Kapaseinhibitorer og anvendelse derav | |
NO20081217L (no) | Nye benzotiazolonderivater | |
NO20083845L (no) | 2,4-diaminopyrimidiner som celle-cyklus kinase inhibitorer | |
NO20072608L (no) | Biaryloksymetylarenkarboksylsyrer | |
MX2009008756A (es) | Compuesto macrociclico. | |
UA83057C2 (ru) | Замещенные производные диоксида тиазолбензоизотиазола и их применение | |
NO20075617L (no) | 4-fenyl-5-okso-1,4,5,6,7,8-heksahydrokinolinderivater for behandling av infertilitet | |
ATE415395T1 (de) | Benzofuran- und benzothiophenderivate, die sich für die behandlung von herzkreislauferkrankungen eignen | |
NO20072089L (no) | Benzimidazolderivater, sammensetninger som inneholder dem, fremstilling derav og anvendelse derav |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |